Table 1 Characteristics of the trials included in the analysis
From: Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
Author | Year | Patient age (treatment/control) | Setting | Design | Cases | Disease course | Initial treatmenta (treatment/control) | Retreatmenta (treatment/control) | Follow-up | NOS /MINORS |
|---|---|---|---|---|---|---|---|---|---|---|
Burns et al. [14] | 2008 | 22/20 months | US | RCT | 12/12 | 2–7 days | IVIG 2 | Infliximab 5/IVIG 2 | Study entry 1–2 weeks 6–8 weeks < 7 months | – |
Youn et al. [15] | 2016 | 3 months-13 years | Korea | RCT | 11/32 | 3–8 days | IVIG 2 | Infliximab 5/IVIG 2 | Study entry 2–4 weeks | – |
Tremoulet et al. [16] | 2014 | 3.0/2.8 years | US | RCT | 98/98 | 3–10 days | IVIG 2 + Infliximab 5 IVIG 2 + Normal saline | IVIG 2 | Study entry 2–5 weeks | – |
Son et al. [27] | 2011 | 23/29 months | US | Retrospective | 20/86 | 4–7 days | IVIG 2 | Infliximab 5/IVIG 2 | Study entry 1–10 weeks | 8 |
Masaaki et al. [28] | 2018 | 2.5/3.0 years | Japan | RCT | 16/15 | 6-7 days | IVIG 2 | Infliximab 5 | Study entry 8 week | – |
Miura et al. [8] | 2005 | N/A | Japan | RCT | 11/11 | N/A | IVIG 2 | IVMP 30 for 3 consecutive days/IVIG 2 | Study entry 1 week | – |
Furakawa et al. [9] | 2007 | 31.3/28.1 months | Japan | Non-RCT | 44/19 | N/A | IVIG 2 | IVMP 30 for 3 consecutive days/IVIG 2 | 4 weeks | 19 |
Miura et al. [10] | 2008 | 32 ± 19/32 ± 26 months | Japan | RCT | 7/8 | 4–5 days | IVIG 2 | IVMP 30 for 3 consecutive days/IVIG 2 | Study entry 1 week | – |
Ogata et al. [11] | 2009 | 14 ± 17/33 ± 24 months | Japan | RCT | 13/14 | 4–5 days | IVIG 2 | IVMP 30 for 3 consecutive days/IVIG 2 | Before discharge | – |
Teraguchi et al. [12] | 2013 | 1–120 months | Japan | Non-RCT | 14/27 | N/A | IVIG 2 | IVMP 30 for 3 consecutive days | 4 weeks | 20 |
Sundel et al. [30] | 2003 | 4.3/4.5 years | US | RCT | 18/21 | 6.5/6.9 days | IVIG 2 + IVMP 30/IVIG 2 | N/A | 2 and 6 weeks | – |
Newburger et al. [29] | 2007 | 2.9/2.9 years | US | RCT | 101/97 | 4–10 days | IVIG 2 + IVMP 30/IVIG 2 | IVIG 2 | Study entry 1 and 5 weeks | – |